A prospective, real-world study analysing efficacy of Galcanezumab for the treatment of migraine in Korea
Latest Information Update: 23 Mar 2022
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
- 18 Mar 2022 Results published in the Cephalalgia
- 29 Sep 2021 New trial record
- 12 Sep 2021 Results (n=54) presented at The International Headache Congress - International Headache Society with the European Headache Federation Joint Congress 2021